Business
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies ...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nNuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nNuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies\nCanada NewsWire\nMISSISSAUGA, ON, March 1, 2016\n\n\n\n- Nuvo Pharmaceuticals Inc. and Crescita Therapeutics Inc. to commence independent trading on March 7, 2016 -\n\n\n\nMISSISSAUGA, ON, March 1, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo Pharma or the Company), formerly known as Nuvo Research Inc. and Crescita Therapeutics Inc. (TSX:CTX) (Crescita), today announced the completion of the reorganization of Nuvo Research Inc. into two separate publicly traded companies (the Reorganization).  As a result of the Reorganization, the shareholders of what was formerly Nuvo Research Inc., now own 100% of Nuvo Pharma, a revenue and EBITDA generating commercial healthcare company, and 100% of Crescita, a drug development company.  The Reorganization was approved by the shareholders of Nuvo Research Inc. at a special shareholders meeting on February 18, 2016 and by the Ontario Superior Court of Justice on February 24, 2016.\n\n\"This transaction gives both businesses greater flexibility to focus on, and pursue, their respective growth strategies,\" said John London, President and CEO of Nuvo Pharma.  \"Nuvo Pharma is a profitable business with significant revenue and EBITDA growth potential.\"  \"We are very excited about the launch of Crescita,\" added Dan Chicoine, Chairman and CEO of Crescita.  \"We have exciting technologies, a proven management team that has obtained FDA approval for four topical pharmaceutical products and a strong balance sheet to support our growth.\"\n\nUnder the Reorganization, existing Nuvo Research Inc. share certificates now represent common shares of Nuvo Pharma and the right to receive a share certificate representing an equal number of Crescita common shares.  The distribution record date (the Record Date) for certificates representing Crescita common...